Vol. 29/2020 Issue 58
okładka czasopisma Child Neurology
powiększenie okładki
Journal Info

CHILD NEUROLOGY

Journal of the Polish Society of Child Neurologists

PL ISSN 1230-3690
e-ISSN 2451-1897
DOI 10.20966
Semiannual


Powrót

Nowe leki przeciwpadaczkowe w terapii padaczki u dzieci – czy spełniły pokładane w nich oczekiwania?


New antiepileptic drugs in pediatric epilepsy – did they fulfill the expectation?




Klinika Neurologii Rozwojowej

Neurol Dziec 2014; 23, 46: 11-19
Full text PDF Nowe leki przeciwpadaczkowe w terapii padaczki u dzieci – czy spełniły pokładane w nich



STRESZCZENIE
Leczenie padaczki stanowi duże wyzwanie terapeutyczne, do osiągnięcia sukcesu potrzebne są zarówno prawidłowo ustalone rozpoznanie, jak i skuteczne leki przeciwpadaczkowe. W przedstawionej pracy podjęto próbę udzielenia odpowiedzi na pytanie, czy wprowadzone w ostatnich latach nowe leki przeciwpadaczkowe, które uzyskały rejestrację do stosowania w padaczce dziecięcej w sposób istotny poprawiły opiekę nad chorym dzieckiem z padaczką. Ocenę tę przeprowadzono na podstawie przeglądu piśmiennictwa i przedstawienia wyników badań własnych. Konwencjonalne „stare” leki przeciwpadaczkowe nadal odgrywają dominującą rolę w terapii padaczki i wciąż pozostają lekami pierwszego rzutu. Nowe leki przeciwpadaczkowe niewątpliwie przyczyniły się do zwiększenia odsetka pacjentów wolnych od napadów oraz tych ze znaczną poprawą, jednak w ocenie długoterminowej nie do końca spełniły pokładane w nich nadzieje. Jest to jeden z niewielu przykładów w medycynie, gdzie „stare” leki mimo wielu wad nie zostały wyparte z leczenia na korzyść leków nowych. Oczywiście poszukiwania nowych cząsteczek będą kontynuowane, bo nadal puste jest miejsce idealnego leku przeciwpadaczkowego.

Słowa kluczowe: leki przeciwpadaczkowe, dzieci


ABSTRACT
Management of epilepsy poses a great challenge for a neurologist. Correct diagnosis, as well as effective treatment, is crucial to achieve success. In the presented study an attempt was made to assess whether newer antiepileptic drugs, which have been introduced in recent years and received authorities’ approval to be applied in childhood epilepsy, significantly improved the health care of children with epilepsy. The review of literature and presentation of own data was included in this study. Conventional “old” antiepileptic drugs still play a dominant role in epilepsy therapy and still remain the first line drugs. New antiepileptic agents have contributed undoubtedly to increase the percentage of seizure free patients or, at least, with marked improvement. However, new antiepileptic drugs have not fulfilled all expectations in long term outcome. For this reason old antiepileptic drugs still have not been replaced by the new ones, nowadays a rare instance in medicine. Nevertheless, the research on new molecules will be continued as the ideal antiepileptic drug still has not been discovered.

Key words: antiepileptic drugs, children


PIŚMIENNICTWO
[] 
Eadie M.J.: Cortical epileptogenesis--Hughlings Jackson and his predecessors. Epilepsia 2007; 48: 2010-2015.
[] 
Friedlander W.J.: Who was ‚the father of bromide treatment of epilepsy’? Arch Neurol 1986; 43: 505-507.
[] 
Lopez-Munoz F., Ucha-Udabe R., Alamo C.: The history of barbiturates a century after their clinical introduction. Neuropsychiatr Dis Treat 2005; 1: 329–343.
[] 
Dodson W.E., Fish D.R., Perucca E., et al.: The Treatment of epilepsy [print], 2nd ed., Blackwell Science, Malden, MA, 2004.
[] 
Reynolds E.H.: Milestones in epilepsy*. Epilepsia 2009; 50: 338–342.
[] 
Cretin B., Hirsch E.: Adjunctive antiepileptic drugs in adult epilepsy: how the first add-on could be the last. Expert Opin Pharmacother 2010; 11: 1053–1067.
[] 
Loscher W., Schmidt D.: Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma. Epilepsia 2010; 52: 657–678.
[] 
Schmidt D.: Efficacy of new antiepileptic drugs. 2011 Epilepsy Curr 11: 9–11.
[] 
Mazurkiewicz-Bełdzińska M.: Skuteczność, objawy niepożądane i wpływ na jakość życia nowych leków przeciwpadaczkowych w terapii padaczki u dzieci i młodzieży – praca habilitacyjna Annales Acad Med Ged 2011; XLV.
[] 
Ben-Menachem E., Sander J.W., Privitera M., et al.: Measuring outcomes of treatment with antiepileptic drugs in clinical trials. Epilepsy Behav 2011; 18: 24–30.
[] 
European Medicines Agency (EMEA) Guideline on clinical investigation of medicinal products inthe treatment of epileptic disorders. CHMP/ EWP/566/98/Rewizja: 2. Styczeń 2010.
[] 
Duchowny M., Pellock J.M., Graf W.D., et al.: A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children. Lamictal Pediatric Partial Seizure Study Group. Neurology 1999; 53: 1724–1731.
[] 
Lhatoo S.D., Wong I.C., Polizzi G., et al.: Long-term retention rates of lamotrigine, gabapentin, and topiramate in chronic epilepsy. Epilepsia 2000; 41: 1592–1596.
[] 
Knoester P.D., Keyser A., Renier W.O., et al.: Effectiveness of lamotrigine in clinical practice: results of a retrospective population-based study. Epilepsy Res 2005; 65: 93–100.
[] 
Besag F.M., Wallace S. J., Dulac O., et al.: Lamotrigine for the treatment of epilepsy in childhood. J Pediatr 1995; 127: 991–997.
[] 
Kluger G., Berz K., Holthausen H.: The long-term use of vigabatrin and lamotrigine in patients with severe childhood onset epilepsy. Eur J Paediatr Neurol 2001; 5: 37–40.
[] 
Motte J., Trevathan E., Arvidsson J.F., et al.: Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. N Engl J Med 1997; 337: 1807–1812.
[] 
Stenbom Y., Tonnby B., Hagberg, B.: Lamotrigine in Rett syndrome: treatment experience from a pilot study. Eur Child Adolesc Psychiatry 1998; 7: 49–52.
[] 
Cianchetti C., Pruna D., Coppola G., et al.: Low-dose lamotrigine in West syndrome. Epilepsy Res 2002; 51: 199–200.
[] 
Aberg L., Heiskala H., Vanhanen, S.L., et al.: Lamotrigine therapy in infantile neuronal ceroid lipofuscinosis (INCL). Neuropediatrics 1997; 28: 77–79.
[] 
Fakhoury T.A., Hammer A.E., Vuong A., et al.: Efficacy and tolerability of conversion to monotherapy with lamotrigine compared with valproate and carbamazepine in patients with epilepsy. Epilepsy Behav 2004; 5: 532–538.
[] 
Mazurkiewicz-Beldzinska M., Szmuda M., Matheisel A.: Long-term efficacy of valproate versus lamotrigine in treatment of idiopathic generalized epilepsies in children and adolescents. Seizure 2010; 19: 195–197.
[] 
Grosso S., Franzoni E., Iannetti P., et al.: Efficacy and safety of topiramate in refractory epilepsy of childhood: long-term follow-up study. J Child Neurol 2005; 20: 893–897.
[] 
Unalp A., Uran N., Hizli T., et al.: Topiramate as a long-term therapy in children with refractory epilepsy. Neurosciences (Riyadh) 2008; 13: 391–394.
[] 
Glauser T.A., Levisohn P.M., Ritter F., et al.: Topiramate in Lennox-Gastaut syndrome: open-label treatment of patients completing a randomized controlled trial. Topiramate YL Study Group. Epilepsia 2000; 41 Suppl 1: 86–90.
[] 
Loscher W., Schmidt D.: Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs. Epilepsia 2006; 47: 1253–1284.
[] 
Stolarek I., Blacklaw J., Forrest G., et al.: Vigabatrin and lamotrigine in refractory epilepsy. J Neurol Neurosurg Psychiatry 1994; 57: 921–924.
[] 
Pina-Garza J.E., Espinoza R., Nordli D., et al.: Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology 2005; 65: 1370–1375.
[] 
Li J., Xiao N., Chen, S.: Efficacy and tolerability of levetiracetam in children with epilepsy. Brain Dev 33: 145–151.
[] 
Obeid M., Pong A.W.: Efficacy and tolerability of high oral doses of levetiracetam in children with epilepsy. Epilepsy Res 91: 101–105.
[] 
Coppola G., Mangano S., Tortorella G., et al.: Levetiracetam during 1-year follow-up in children, adolescents, and young adults with refractory epilepsy. Epilepsy Res 2004; 59: 35–42.
[] 
Peake D., Mordekar S., Gosalakkal J., et al.: Retention rate of levetiracetam in children with intractable epilepsy at 1 year. Seizure 2007; 16: 185–189.
[] 
Chappell B., Crawford P.: An audit of lamotrigine, levetiracetam and topiramate usage for epilepsy in a district general hospital. Seizure 2005; 14: 422–428.
[] 
Rosenow F., Schade-Brittinger C., Burchardi N., et al.: The LaLiMo Trial: lamotrigine compared with levetiracetam in the initial 26 weeks of monotherapy for focal and generalised epilepsy--an open-label, prospective, randomised controlled multicenter study. J Neurol Neurosurg Psychiatry 83: 1093–1098.
[] 
Baulac M., Leon T., O’Brien T.J., et al.: A comparison of pregabalin, lamotrigine, and placebo as adjunctive therapy in patients with refractory partial-onset seizures. Epilepsy Res 91: 10–19.
[] 
Camfield P., Camfield C., Smith S., et al.: Long-term outcome is unchanged by antiepileptic drug treatment after a first seizure: a 15-year follow-up from a randomized trial in childhood. Epilepsia 2002; 43: 662– 663.
[] 
Ding Y.X., Zou L.P., Ma M.S., et al.: Retrospective analysis of the effectiveness of first-line antiepileptic drugs for generalized onset and unclassified epileptic seizures in Chinese children. Childs Nerv Syst 27: 279–284.
[] 
Elger C.E., Fernandez G.: Options after the first antiepileptic drug has failed. Epilepsia 1999; 40 Suppl 6:S9-12; discussion 73–14.
[] 
Kwan P., Brodie, M.J.: Effectiveness of first antiepileptic drug. Epilepsia 2001; 42: 1255–1260.
[] 
Nonoda Y., Iwasaki T., Ishii M.: The efficacy of gabapentin in children of partial seizures and the blood levels. Brain Dev 36: 194–202.
[] 
Appleton R., Fichtner K., LaMoreaux L., et al.: Gabapentin as add-on therapy in children with refractory partial seizures: a 24-week, multicentre, open-label study. Dev Med Child Neurol 2001; 43: 269–273.
[] 
Khan R.B., Hunt D.L.,Thompson S.J.: Gabapentin to control seizures in children undergoing cancer treatment. J Child Neurol 2004; 19: 97–101.
[] 
Lindberger M., Alenius M., Frisen L., et al.: Gabapentin versus vigabatrin as first add-on for patients with partial seizures that failed to respond to monotherapy: a randomized, double-blind, dose titration study. GREAT Study Investigators Group. Gabapentin in Refractory Epilepsy Add-on Treatment. Epilepsia 2000; 41: 1289–1295.
[] 
Schmidt D., Gram L., Brodie M., et al.: Tiagabine in the treatment of epilepsy – a clinical review with a guide for the prescribing physician. Epilepsy Res 2000; 41: 245–251.
[] 
Arroyo S., Boothman B.R., Brodie M.J., et al.: A randomised open-label study of tiagabine given two or three times daily in refractory epilepsy. Seizure 2005; 14: 81–84.
[] 
Genton P., Guerrini R., Perucca, E.: Tiagabine in clinical practice. Epilepsia 2001; 42 Suppl 3: 42–45.
[] 
Balslev T., Uldall P., Buchholt J.: Provocation of non-convulsive status epilepticus by tiagabine in three adolescent patients. Eur J Paediatr Neurol 2000; 4: 169–170.
[] 
Uldall P., Bulteau C., Pedersen S.A., et al.: Tiagabine adjunctive therapy in children with refractory epilepsy: a single-blind dose escalating study. Epilepsy Res 2000; 42: 159–168.
[] 
Bauer J., Bergmann A., Reuber M., et al.: Tolerability of tiagabine: a prospective open-label study. Epileptic Disord 2002; 4: 257–260.
[] 
Jedrzejczak J.: Tiagabine as add-on therapy may be more effective with valproic acid--open label, multicentre study of patients with focal epilepsy. Eur J Neurol 2005; 12:176–180.
Powrót
 

Most downloaded
Semiologiczna i psychiatryczna charakterystyka dzieci z psychogennymi napadami rzekomopadaczkowymi
Neurol Dziec 2018; 27, 55: 11-14
Autyzm dziecięcy – współczesne spojrzenie
Neurol Dziec 2010; 19, 38: 75-78
Obraz bólów głowy w literaturze pięknej i poezji na podstawie wybranych utworów
Neurol Dziec 2016; 25, 50: 9-17

Article tools
Export Citation
Format:

Scholar Google
Articles by:Mazurkiewicz-Bełdzińska M

PubMed
Articles by:Mazurkiewicz-Bełdzińska M


Copyright © 2017 by Polskie Towarzystwo Neurologów Dziecięcych